METASTATIC SOLID TUMORS

This study tests a new combination of drugs (RAS(ON) inhibitors plus ivonescimab) in adults with advanced or metastatic solid tumors that have a RAS mutation. The goal is to see if the combination is safe and can shrink tumors or slow their growth. About 370 people with cancers l…

This study tests a new drug called repotrectinib in people with advanced solid tumors that have specific gene changes (ALK, ROS1, or NTRK). The goal is to see if the drug can shrink tumors and control the cancer. About 500 adults will take part, and the study has two phases: firs…

This early study tests a new treatment for people with stage 4 solid tumors that have stopped responding to standard care. Patients receive an injection of tiny iron-oxide nanoparticles that travel to the tumor, then a magnetic field machine heats the particles to damage cancer c…

This study tests a new drug called AVZO-103 in people with advanced bladder cancer or other solid tumors that have spread. The drug is designed to attack cancer cells directly. The main goals are to find a safe dose and see if it shrinks tumors. About 355 adults will take part.

This early-phase study tests a new cancer drug, ADCX-020, in about 290 adults with advanced solid tumors that have stopped responding to standard treatments. The drug is an antibody-drug conjugate designed to target and kill cancer cells. The study first finds a safe dose, then t…

This early-phase study tests an experimental drug called MK-0472, given alone or with other cancer drugs (pembrolizumab or MK-1084), in people with advanced solid tumors that have spread. The main goals are to check safety, find the right dose, and see if the drug helps control t…

This early-stage trial tests a new drug called SKB107 in people with advanced solid tumors that have spread to the bone. The main goal is to check the drug's safety and how the body processes it. About 90 adults aged 18-75 who have tried other treatments without success may join.…

This early-phase study tests a new drug called INCA33890 in about 408 adults with advanced or metastatic solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, find the best dose, and see if it can shrink tumors. Participants m…

This study tests a new experimental drug called CKD-512, given alone or with another cancer drug (pembrolizumab), in people with advanced solid tumors that have not responded to standard treatments. The main goals are to find a safe dose and check for early signs of tumor shrinka…

This study tests a new drug called AVZO-1418 in people with advanced solid tumors that have spread. The goal is to find a safe dose and see if it shrinks tumors. About 430 adults will take part. The drug is given through a vein, alone or with other treatments.

This early-phase study tests a new experimental drug called BGB-53038 in people with advanced or metastatic solid tumors that have a specific genetic change (KRAS mutation or amplification). The drug is a pan-KRAS inhibitor, meaning it aims to block many forms of the faulty KRAS …

This early-stage study tests a new drug called ERAS-0015 in people with advanced solid tumors that have certain RAS mutations and have not responded to standard treatments. The main goal is to check the drug's safety and find the best dose, either alone or with other drugs. About…

This early-phase study tests a new drug called SLV-324 in about 70 adults with metastatic solid tumors that have worsened after standard treatments. The main goal is to find the safest dose and check how the drug affects the body and tumors. This is not a cure, but aims to contro…

This early-stage trial tests a new drug called DS3610a in 70 adults with advanced or metastatic solid tumors that have stopped responding to standard treatments. The main goals are to check the drug's safety and find the right dose. This is a first-in-human study, so it focuses o…

This study tests a new drug called raludotatug deruxtecan (R-DXd) in people with advanced or metastatic solid tumors that have not responded to other treatments. The goal is to see if the drug can shrink tumors or slow disease progression. About 200 adults will take part, and the…

This study tests a drug called repotrectinib in children and young adults (up to age 25) with advanced solid tumors or lymphomas that have specific genetic changes (ALK, ROS1, or NTRK1-3). The first part finds the safest dose, and the second part checks how well the drug shrinks …

This study tests an experimental drug called RO7566802, given alone or with another drug (atezolizumab), in people with advanced solid tumors that have not responded to standard treatments. The main goal is to check the safety and find the best dose. About 250 adults with incurab…

This early-stage study tests a new drug called ERAS-4001 in people with advanced solid tumors that have certain KRAS mutations. The main goal is to see if the drug is safe and tolerable when given alone or with other treatments. About 200 participants will take part to help find …